AVEO Pharmaceuticals Inc., a Cambridge, Mass.-based oncology drug company, has raised $53 million in Series D funding. New investors include: Biogen Idec, Bessemer Venture Partners, Merlin BioMed Group, Mitsubishi UFJ Financial Group and Vatera Holdings, an investment vehicle owned by Kos Pharma founder Michael Jaharis. Return backers include: